Search results
Showing 3271 to 3285 of 7691 results
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee. This is called the highly specialised
Our role in the Innovative Licensing and Access Pathway (ILAP)
The Innovative Licensing and Access Pathway (ILAP) aims to streamline patient access to safe, financially sustainable and innovative medicines.
Our policies and procedures on topics including declarations of interest, gifts and hospitality, complaints, and more.
Guidance Executive
NICE's research work and partnerships with researchers, funders, charities and policy organisations.
Interim process and methods statement for bringing together NICE guidance (PMG47)
This interim process and methods statement sets out the general principles guiding NICE's approach to including NICE technology appraisal recommendations in guideline topic areas. It also describes what the key changes are to existing methods and processes
Show all sections
- Overview
- Introduction
- 1 Why we are bringing together NICE guidance
- 2 Process and methods for incorporating NICE technology appraisals into NICE guideline topic areas
- 3 Approach to further development of process and methods for bringing together NICE guidance
- 4 Updates to this interim process and methods statement
Links to our annual reports and business plan
NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social...
This guide describes the process NICE uses to develop NICE quality standards
Charging procedure: technology appraisal and highly specialised technologies evaluations
Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly
This indicator covers the proportion of patients with acute myocardial infarction who were discharged on dual antiplatelet therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG95
This indicator covers the time between call for help and balloon inflation for patients with ST segment elevation myocardial infarction (STEMI) undergoing reperfusion by primary percutaneous coronary intervention (PCI). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG93
This indicator covers the proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had balloon inflation for primary percutaneous coronary intervention (PCI) in less than 60 minutes from time of admission at a centre with primary PCI facilities. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG92
This indicator covers the proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had coronary reperfusion therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG91
This indicator covers proportion of pregnant women accessing antenatal care who are seen for booking by 10 weeks and 0 days. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG81